Compare Apple Inc (AAPL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Sanofi SA — how do they compare? Apple Inc trades at $302.24 (market cap $4.45T), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Apple Inc is far larger — about 42.7× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| AAPL | SNY | |
|---|---|---|
Market Cap | $4.45T | $104.30B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $52.34 |
52-Week Low | $224.90 | $41.33 |
Enterprise Value | $4.47T | $124.19B |
Dividend Yield | 0.35% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.14, down 2.31% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 26.91%. However, valuation ratios like P/E of 34.97 and P/B of 41.39 appear elevated. Recent news highlights AI potential through its device ecosystem but also store closures and union disputes.
The outlook is mixed: solid fundamentals and analyst buy consensus support upside to the $337.63 price target, but high valuations and technical bearishness near-term pose risks. Key opportunities include AI integration and cash flow strength; risks involve competitive pressures, regulatory scrutiny, and execution on growth initiatives.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
